|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | PI3K/Akt/mTOR inhibitors in breast cancer显示文摘Activation of the phosphoinositide 3 kinase(PI3K)/Akt/mammalian target of rapamycin(mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase Ⅰ to Ⅲ trials involving inhibitors of the pathway have been or are being conducted in solid tumors and breast cancer. Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor(HR)-positive, human epidermal growth factor receptor 2(HER2)-negative breast cancer. In this review, we summarise the efficacy and toxicity findings from the randomised clinical trials, with simplified guidelines on the management of potential adverse effects. Education of healthcare professionals and patients is critical for safety and compliance. While there is some clinical evidence of activity of mTOR inhibition in HR-positive and HER2-positive breast cancers, the benefits may be more pronounced in selected subsets rather than in the overall population. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the PI3K/Akt/mTOR(PAM) pathway. | Joycelyn JX Lee Kiley Loh Yoon-Sim Yap | 2015 | Cancer Biology & Medicine2015，12，4： | 21 |
| 2 | The call to action 显示文摘 | Joycelyn ME | 1999 | Child Abuse & Neglect1999，23，10： | 1 |
| 3 | Breakthrough invasive fungal diseases during echinocandin treatment in high-risk hospitalized hematologic patients显示文摘 | Thomas S. Y. Chan Harinder Gill Yu-Yan Hwang Joycelyn Sim Alan C. T. Tse Florence Loong Pek-Lan Khong Eric Tse Anskar Y. H. Leung Chor-Sang Chim Albert K. W. Lie Yok-Lam Kwong | 2014 | Annals of Hematology2014，，3： | 1 |
| 4 | Cancer Pain Management and the JCAHO’s Pain Standards显示文摘 | Marlene Zichi Cohen Mary K Easley Coni Ellis Beverly Hughes Kristin Ownby Beverly Green Rashad Mari Rude Ellen Taft Joycelyn Bailey Westbrooks | 2003 | Journal of Pain and Symptom Management2003，，6： | 1 |
| 5 | Analysis of a cone snail’s killer cocktail – The milked venom of Conus geographus显示文摘 | Jon-Paul Bingham Margaret R. Baker Joycelyn B. Chun | 2012 | Toxicon2012，，6： | 1 |
| 6 | Cone snail milked venom dynamics – A quantitative study of Conus purpurascens显示文摘 | Joycelyn B.S. Chun Margaret R. Baker Do H. Kim Majdouline LeRoy Priamo Toribo Jon-Paul Bingham | 2012 | Toxicon2012，，1： | 1 |
| 7 | A Phase II Study of Oportuzumab Monatox: An Immunotoxin Therapy for Patients with Noninvasive Urothelial Carcinoma In Situ Previously Treated with Bacillus Calmette-Guérin显示文摘 | Mark Kowalski Jacinthe Guindon Louise Brazas Celine Moore Joycelyn Entwistle Jeannick Cizeau Michael A.S. Jewett Glen C. MacDonald | 2012 | The Journal of Urology2012，，5： | 1 |
| 8 | Development of catalyst-free carbon-sulfur bond formation reactions under aqueous media and their applications显示文摘Methods for the carbon-sulfur bond formation under catalyst-free,aqueous conditions are extremely useful in organic synthesis and chemical biology.Our laboratory has developed methodologies to construct carbon-thiol bonds,carbon-sulfinic acid bonds,and carbon-disulfide bonds and such methodologies have been widely adopted by other research groups over multidisciplinary fields.In this article,our work on C-S bond formation in an aqueous solvent and its corresponding applications is summarized. | Min Sun Kang Joycelyn Yi Xin Khoo Zhenhua Jia Teck-Peng Loh | 2022 | Green Synthesis and Catalysis2022，3，4： | 0 |
| 9 | Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience显示文摘BACKGROUND Invasive lobular carcinomas(ILC)form 5%-10%of breast cancer and rarely show overexpression of human epidermal growth factor receptor 2(HER2).AIM To describe the prevalence and prognostic factors of HER2 positive(HER2+)ILC in an Asian population.METHODS A retrospective review of patients with ILC seen between January 1985 and March 2018 at various SingHealth medical institutions was conducted.Demographic and clinical data were collected from medical records.We examined clinicopathological characteristics and survival in relation to HER2 status.RESULTS A total of 864 patients were included.Prevalence of HER2 positivity was 10.1%(87 patients).Compared with HER2 negative(HER2-)ILC,HER2+ILC was associated with a higher proportion of estrogen receptor negative(24.4%vs 5.9%,P<0.001),progesterone receptor negative(PR-)(40.2%vs 24%,P=0.002)and grade 3 tumours(Grade 3,29.0%vs 10.2%,P<0.001).Overall survival rate was poorer in patients with HER2+compared to HER2-ILC(56.7%vs 72.9%alive at 10 years;hazard ratio 1.87,95%confidence interval:1.21-2.90,P=0.004).Based on multivariate analysis,negative prognostic factors for overall survival included HER2 positivity,PR negativity,older age,Indian ethnicity and higher tumour stage.CONCLUSION Prevalence of HER2+ILC was 10.1%.HER2+ILC was more likely to have poorer prognostic features such as estrogen receptor negative,PR-and higher tumour grade,and have a poorer survival. | Ga-Jing Kee Ryan Ying-Cong Tan Sultana Rehena Joycelyn Jie-Xin Lee Ma Wai-Wai Zaw Wei-Xiang Lian Joe Yeong Su-Ming Tan Swee-Ho Lim Benita Kiat-Tee Tan Yoon-Sim Yap Rebecca Alexandra Dent Fuh-Yong Wong Guek-Eng Lee | 2020 | World Journal of Clinical Oncology2020，11，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员